Quantcast
Last updated on April 19, 2014 at 7:50 EDT

Latest Vanda Pharmaceuticals Inc. Stories

2012-01-26 06:00:00

ROCKVILLE, Md., Jan. 26, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that tasimelteon was shown for the first time to reset the body clock and to align it to a constant 24-hour day in patients suffering from Non-24-Hour Sleep-Wake Disorder (Non-24-Hour Disorder). Tasimelteon is a circadian regulator in development for the treatment of Non-24-Hour Disorder in totally blind individuals with no light perception. This observation was made in four...

2012-01-18 18:00:00

ROCKVILLE, Md., Jan. 18, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the fourth quarter of 2011, on Tuesday, February 14, 2012, before the market opens. The Company will host a conference call at 10:00 AM ET on Tuesday, February 14, 2012 during which Vanda management will discuss the financial...

2011-12-13 06:00:00

ROCKVILLE, Md., Dec. 13, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Megapharm Ltd., one of Israel's leading private biotech, pharmaceutical and medical nutrition marketing companies, for the commercialization of Fanapt(TM) in Israel. "We are excited to reach this step on the...

2011-11-04 06:00:00

ROCKVILLE, Md., Nov. 4, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2011. "We are excited with our progress this quarter and especially as it relates to our efforts on tasimelteon," said Mihael Polymeropoulos, M.D., President and...

2011-10-24 16:00:00

ROCKVILLE, Md., Oct. 24, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has named Bob Repella as Senior Vice President, Chief Commercial Officer of the company. Mr. Repella has more than 25 years of experience in the biotech/pharmaceutical industry, including senior-level leadership roles in global marketing, sales, new product development and commercial operations. "We are very pleased to welcome Bob to the Vanda team," said Mihael...

2011-10-18 18:00:00

ROCKVILLE, Md., Oct. 18, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the third quarter of 2011, on Friday, November 4, 2011, before the market opens. The Company will host a conference call at 10:00 AM ET on Friday, November 4, 2011, during which Vanda management will discuss the financial...

2011-09-14 18:00:00

ROCKVILLE, Md., Sept. 14, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda's President and CEO will deliver a corporate presentation at the UBS Global Life Sciences Conference in New York City on Tuesday, September 20, 2011 at 12:30 p.m. Eastern Time. Dr. Polymeropoulos'...

2011-08-31 18:00:00

ROCKVILLE, Md., Aug. 31, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda President and CEO will deliver a corporate presentation at the Stifel Nicolaus Global Healthcare Conference in Boston, MA on Thursday, September 8, 2011 at 4:25 pm Eastern Time. Dr. Polymeropoulos'...

2011-08-04 06:00:00

ROCKVILLE, Md., Aug. 4, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2011. "We are pleased with our progress towards our vision of building a CNS specialty pharmaceutical company. Fanapt® scripts in the U.S....

2011-08-01 06:00:00

ROCKVILLE, Md., August 1, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Argentina-based Biotoscana Farma S.A., a wholly owned affiliate of Biotoscana International, based in Bogota, Colombia, for the commercialization of Fanapt (TM) in Argentina. "We are very excited to achieve this...